Colorectal cancer (CRC) liver metastasis (CLM) is the leading death cause of CRC patients, but there is no satisfied approach to treat CLM. Gut microbiota plays a pivotal role in CRC initiation and development. Targeting dysbiosis of the gut microbiota might open up new opportunities for CLM treatment. Here, we investigated the efficacy of sodium butyrate (NaB), a major product of gut microbial fermentation, in modulating gut microbiota in CLM mice. NaB supplement decreased mouse colon cancer CT26 cell liver metastasis in intrasplenic tumor injection model of BALB/c mice. Using 16S rRNA gene sequencing, we found altered microbiota composition in CLM mice, characterized by increases of Firmicutes and Proteobacteria. NaB beneficially changed dysbiosis in CLM mice. Functional analysis of the KEGG pathways showed that NaB changed pathways related to immune system diseases and primary immunodeficiency in CLM mice. In addition, NaB decreased T regulatory cells and increased natural killer T cells and T helper 17 cells, accordingly decreased IL-10 and increased IL-17 secretion in CLM mice liver. In conclusion, NaB beneficially modulated gut microbiota and improved host immune response in CLM mice. These findings demonstrate the therapeutic potential of NaB in CLM treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10565-020-09518-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.
Nature
January 2025
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ receptor (LTβR) pathway, the inflammatory signals and cells that induce TLSs remain incompletely identified. Here we show that interleukin-33 (IL-33), the alarmin released by inflamed tissues, induces TLSs.
View Article and Find Full Text PDFDesign of a Glycoconjugate Vaccine Against Paratyphi A.
Vaccines (Basel)
November 2024
GSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
Background/objectives: Typhoid and paratyphoid fever together are responsible for millions of cases and thousands of deaths per year, most of which occur in children in South and Southeast Asia. While typhoid conjugate vaccines (TCVs) are licensed, no vaccines are currently available against Paratyphi A. Here we describe the design of a Paratyphi A conjugate.
View Article and Find Full Text PDFIntegrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma.
Nat Commun
November 2024
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Genomic profiling often fails to predict therapeutic outcomes in cancer. This failure is, in part, due to a myriad of genetic alterations and the plasticity of cancer signaling networks. Functional profiling, which ascertains signaling dynamics, is an alternative method to anticipate drug responses.
View Article and Find Full Text PDFNon-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade.
Nat Commun
October 2024
Gustave Roussy, INSERM U1030, Université Paris-Saclay, Villejuif, France.
Article Synopsis
- The study investigates how different doses of radiotherapy (RT) affect the tumor immune environment and explores a strategy that combines low dose RT (LDRT) with high dose RT (HDRT) to enhance anti-tumor responses.
- Researchers conducted experiments on colorectal and breast cancer models in mice, finding that a technique called partial irradiation (PI) improved tumor control when paired with an immune treatment (anti-PD1).
- Results showed that PI reshaped immune cells in the tumor, increasing their ability to fight cancer, while also suggesting that adding a certain drug (CXCR2 antagonist) alongside RT and immunotherapy can enhance tumor control and survival rates.
GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency.
Nat Commun
October 2024
Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, tanford, CA, USA.
The intensive nutrient requirements needed to sustain T cell activation and proliferation, combined with competition for nutrients within the tumor microenvironment, raise the prospect that glucose availability may limit CAR-T cell function. Here, we seek to test the hypothesis that stable overexpression (OE) of the glucose transporter GLUT1 in primary human CAR-T cells would improve their function and antitumor potency. We observe that GLUT1OE in CAR-T cells increases glucose consumption, glycolysis, glycolytic reserve, and oxidative phosphorylation, and these effects are associated with decreased T cell exhaustion and increased Th differentiation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!